Correction to: Cost–consequence analysis of fluticasone furoate/vilanterol for asthma management in Spain: an analysis based on the Salford Lung Study in asthma

Correction to: The European Journal of Health Economics https://doi.org/10.1007/s10198-019-01101-x

In the published article, the Table 1 was published incorrectly.

The correct Table 1 is given below

Variables	FF/VI 184/22 mcg and 92/22 mcg	UC group
Monthly drug costs [17, 21]	€51.52a	ICS = €18.75b ICS/LABA = €48.25b
Annual drug costs (€, 2018)	€627.26	€557.31
Asthma management direct annual costs (€, 2018)c [19, 20]
Uncontrolled (ACT score ≤ 15)	€1919.01
Partially controlled (ACT score 16–19)	€1015.61
Well-controlled (ACT score ≥ 20)	€656.90
Assumed proportion of days covered,  %	100	100
Assumed current uptake,  %	10	90
Assumed new uptake,  %	20	80
Percentage of subjects in each ACT category (ITT population, n = 4233) [18]
Baseline
Uncontrolled	41%	41%
Partially controlled	31%	31%
Well-controlled	28%	28%
24 weeks
Uncontrolled	20%	29%
Partially controlled	20%	25%
Well-controlled	60%	46%
52 weeks
Uncontrolled	21%	30%
Partially controlled	20%	26%
Well-controlled	59%	44%

1. FF/VI fluticasone furoate/vilanterol, ICS inhaled corticosteroid, ICS/LABA inhaled corticosteroid/long-acting beta-agonist, ACT Asthma Control Test, ITT intention-to-treat
2. ^aPrice to Public plus VAT of FF/VI 184/22 and 92/22 mcg
3. ^bUC cost calculated as a weighted average drug cost of all available presentations at Price to Public plus VAT
4. ^cCosts annualised at updated to 2018